CL2014000504A1 - Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. - Google Patents

Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.

Info

Publication number: CL2014000504A1
Authority: CL; Chile
Prior art keywords: hypertension; diseases; prevention; treatment; pharmaceutical composition
Prior art date: 2011-09-02

Application number

CL2014000504A

Other languages

English (en)

Inventor

Dieter Lang

Markus Follmann

Johannes-Peter Stasch

Gorden Redlich

Nils Griebenow

Frank Wunder

Walter Hübsch

Niels Lindner

Alexandros Vakalopoulos

Adrian Tersteegen

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-02

Filing date

2014-02-28

Publication date

2014-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000504(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-02 Priority claimed from DE201110082041 external-priority patent/DE102011082041A1/de

2012-01-11 Priority claimed from DE201210200351 external-priority patent/DE102012200351A1/de

2014-02-28 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2014-10-03 Publication of CL2014000504A1 publication Critical patent/CL2014000504A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CL2014000504A 2011-09-02 2014-02-28 Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. CL2014000504A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE201110082041 DE102011082041A1 (de)	2011-09-02	2011-09-02	Substituierte annellierte Pyrimidine und ihre Verwendung
DE201210200351 DE102012200351A1 (de)	2012-01-11	2012-01-11	Substituierte annellierte Pyrimidine und ihre Verwendung

Publications (1)

Publication Number	Publication Date
CL2014000504A1 true CL2014000504A1 (es)	2014-10-03

Family

ID=47755368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000504A CL2014000504A1 (es)	2011-09-02	2014-02-28	Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.

Country Status (28)

Country	Link
US (2)	US8859569B2 (es)
EP (1)	EP2751106B1 (es)
JP (1)	JP6054967B2 (es)
KR (1)	KR20140068112A (es)
CN (1)	CN104039784B (es)
AP (1)	AP2014007541A0 (es)
AR (1)	AR087769A1 (es)
AU (1)	AU2012300844B2 (es)
BR (1)	BR112014005110A2 (es)
CA (1)	CA2847075A1 (es)
CL (1)	CL2014000504A1 (es)
CO (1)	CO6950471A2 (es)
CR (1)	CR20140096A (es)
CU (1)	CU20140025A7 (es)
DO (1)	DOP2014000043A (es)
EA (1)	EA026701B1 (es)
EC (1)	ECSP14013224A (es)
GT (1)	GT201400033A (es)
HK (1)	HK1198698A1 (es)
IL (1)	IL231244A (es)
MA (1)	MA35365B1 (es)
MX (1)	MX348470B (es)
PE (1)	PE20141582A1 (es)
PH (1)	PH12014500460A1 (es)
SG (1)	SG11201400083VA (es)
TW (1)	TWI565708B (es)
UY (1)	UY34306A (es)
WO (1)	WO2013030288A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3002298T (lt)	2007-11-21	2019-12-10	Univ Oregon Health & Science	Monokloniniai antikūnai prieš faktorių xi ir jų panaudojimo būdai
TR201904662T4 (tr)	2008-12-18	2019-05-21	Gruber Andras	Anti-fxı antikorları ve kullanma yöntemleri.
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (de)	2010-07-09	2014-03-19	Bayer Intellectual Property GmbH	Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
EP2699578B1 (de)	2011-04-21	2016-04-20	Bayer Intellectual Property GmbH	Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
CN105503867B (zh)	2011-11-25	2019-01-11	阿德弗里奥药品有限责任公司	用于制备取代的5-氟-1h-吡唑并吡啶类化合物的方法
CN102491974B (zh) *	2011-12-12	2013-08-07	南京药石药物研发有限公司	1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
DE102012200360A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte Triazine und ihre Verwendung
DE102012200352A1 (de) *	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
WO2013131923A1 (de) *	2012-03-06	2013-09-12	Bayer Intellectual Property Gmbh	Substituierte azabicyclen und ihre verwendung
CA2872926C (en)	2012-05-10	2022-07-05	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014084312A1 (ja)	2012-11-30	2014-06-05	アステラス製薬株式会社	イミダゾピリジン化合物
KR20150119871A (ko)	2013-02-21	2015-10-26	아드베리오 파마 게엠베하	메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태
KR20150121007A (ko) *	2013-03-01	2015-10-28	바이엘 파마 악티엔게젤샤프트	트리플루오르메틸-치환된 고리-융합된 피리미딘 및 그의 용도
WO2014131741A1 (de)	2013-03-01	2014-09-04	Bayer Pharma Aktiengesellschaft	Benzyl-substituierte pyrazolopyridine und ihre verwendung
CA2914100A1 (en)	2013-06-04	2014-12-11	Bayer Pharma Aktiengesellschaft	3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
AU2014289312A1 (en)	2013-07-10	2016-02-11	Bayer Pharma Aktiengesellschaft	Benzyl-1H-pyrazolo(3,4-b)pyridines and use thereof
US9611278B2 (en)	2013-12-11	2017-04-04	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
US20160311826A1 (en)	2013-12-11	2016-10-27	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
WO2015088886A1 (en) *	2013-12-11	2015-06-18	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
WO2015106268A1 (en)	2014-01-13	2015-07-16	Ironwood Pharmaceuticals, Inc.	USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US9688699B2 (en)	2014-02-19	2017-06-27	Bayer Pharma Aktiengesellschaft	3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
EP3152214B1 (en)	2014-06-04	2020-01-29	Merck Sharp & Dohme Corp.	Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CA2959199A1 (en)	2014-08-29	2016-03-03	Bayer Pharma Aktiengesellschaft	Amino-substituted annulated pyrimidines and use thereof
EP3186251A1 (de) *	2014-08-29	2017-07-05	Bayer Pharma Aktiengesellschaft	Substituierte annellierte pyrimidine und ihre verwendung
US10844064B2 (en)	2014-09-17	2020-11-24	Cyclerion Therapeutics, Inc.	sGC stimulators
WO2016073891A1 (en)	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en) *	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
SI3215511T1 (sl)	2014-11-06	2024-07-31	Bial-R&D Investments, S. A.	Substituirani pirazolo(1,5-a)pirimidini in njihova uporaba pri zdravljenju zdravstvenih motenj
TW201625635A (zh)	2014-11-21	2016-07-16	默沙東藥廠	作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
CA2969268A1 (en)	2014-12-02	2016-06-09	Bayer Pharma Aktiengesellschaft	Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
BR112017014770A2 (pt)	2015-01-08	2018-01-16	Advinus Therapeutics Ltd	compostos bicíclicos, composições e aplicações médicas dos mesmos
US10456404B2 (en)	2015-03-13	2019-10-29	Indiana University Research And Technology Corporation	Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
AU2016258847A1 (en)	2015-05-06	2017-11-16	Bayer Pharma Aktiengesellschaft	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc)
WO2016191334A1 (en)	2015-05-27	2016-12-01	Merck Sharp & Dohme Corp.	Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3310782B1 (en)	2015-05-28	2021-12-01	Merck Sharp & Dohme Corp.	Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2017013010A1 (de)	2015-07-23	2017-01-26	Bayer Pharma Aktiengesellschaft	Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
CN108463224A (zh)	2015-12-14	2018-08-28	铁木医药有限公司	sGC刺激剂用于胃肠功能障碍治疗的应用
WO2017107052A1 (en) *	2015-12-22	2017-06-29	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase stimulators
BR112018070586A8 (pt)	2016-04-06	2023-03-14	Lysosomal Therapeutics Inc	Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
WO2017176961A1 (en)	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en)	2016-04-06	2019-09-18	Lysosomal Therapeutics Inc.	PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
BR112018072552A8 (pt)	2016-05-05	2023-03-14	Lysosomal Therapeutics Inc	Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
US11345698B2 (en)	2016-05-05	2022-05-31	Bial—R&D Investments, S.A.	Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
WO2017197555A1 (en)	2016-05-16	2017-11-23	Merck Sharp & Dohme Corp.	Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017200857A1 (en)	2016-05-18	2017-11-23	Merck Sharp & Dohme Corp.	Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
EP3525778A1 (de)	2016-10-11	2019-08-21	Bayer Pharma Aktiengesellschaft	Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
EP3525779B1 (de)	2016-10-11	2024-06-05	Bayer Pharma Aktiengesellschaft	Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
MA46755A (fr)	2016-11-08	2021-06-02	Cyclerion Therapeutics Inc	Stimulateurs de sgc
EP3554488A2 (en)	2016-12-13	2019-10-23	Cyclerion Therapeutics, Inc.	Use of sgc stimulators for the treatment of esophageal motility disorders
CN110312718B (zh)	2017-01-10	2023-02-28	拜耳公司	作为害虫防治剂的杂环烯衍生物
CN108727340B (zh)	2017-04-11	2020-12-29	广东东阳光药业有限公司	氟取代的吲唑类化合物及其用途
RU2662308C1 (ru) *	2017-12-25	2018-07-25	Феркат Адельзянович Халиуллин	Средство для лечения и профилактики тромбоза
JOP20200287A1 (ar)	2018-05-15	2020-11-09	Bayer Ag	بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
US12220414B2 (en)	2018-07-11	2025-02-11	Tisento Therapeutics Inc.	Use of sGC stimulators for the treatment of mitochondrial disorders
WO2020164008A1 (en)	2019-02-13	2020-08-20	Bayer Aktiengesellschaft	Process for the preparation of porous microparticles
SI4106876T1 (sl)	2020-02-18	2025-11-28	Gilead Sciences, Inc.	Protivirusne spojine
TWI775313B (zh)	2020-02-18	2022-08-21	美商基利科學股份有限公司	抗病毒化合物
TWI883391B (zh)	2020-02-18	2025-05-11	美商基利科學股份有限公司	抗病毒化合物
EP3925953A1 (en) *	2020-06-16	2021-12-22	Adverio Pharma GmbH	Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
JP7688152B2 (ja)	2021-04-16	2025-06-03	ギリアードサイエンシーズ，インコーポレイテッド	アミドを使用してカルバヌクレオシドを調製する方法
EP4387977A1 (en)	2021-08-18	2024-06-26	Gilead Sciences, Inc.	Phospholipid compounds and methods of making and using the same
WO2024038398A1 (en) *	2022-08-18	2024-02-22	Torrent Pharmaceuticals Limited	Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses
TW202448469A (zh) *	2023-06-09	2024-12-16	大陸商西藏海思科製藥有限公司	吡咯並[2,3-d]嘧啶-4-胺衍生物及其在醫藥上的應用
CN118203583B (zh) *	2024-04-29	2025-10-03	齐鲁工业大学(山东省科学院)	胸腺嘧啶在制备治疗或预防阿霉素致心脏损伤的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1029653A (en)	1910-05-11	1912-06-18	Waterbury Farrel Foundry Co	Slotting-machine.
GB9314412D0 (en)	1993-07-13	1993-08-25	Rhone Poulenc Agriculture	New compositions of matter
EP0743066A3 (en)	1995-05-16	1998-09-30	Mitsui Pharmaceuticals, Inc.	Wound-healing agent
DE19642255A1 (de)	1996-10-14	1998-04-16	Bayer Ag	Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6451805B1 (en)	1997-11-14	2002-09-17	Bayer Aktiengesellschaft	Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE10021069A1 (de)	2000-04-28	2001-10-31	Bayer Ag	Substituiertes Pyrazolderivat
EP1339716B1 (de)	2000-11-22	2004-11-03	Bayer HealthCare AG	lactam-substituierte pyrazolopyridinderivate
DE10132416A1 (de)	2001-07-04	2003-01-16	Bayer Ag	Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
DE10232571A1 (de)	2002-07-18	2004-02-05	Bayer Ag	4-Aminosubstituierte Pyrimidinderivate
DE602004029025D1 (de)	2003-05-09	2010-10-21	Asahi Glass Co Ltd	Verfahren zur herstellung von 3-substituiertem 2-chlor-5-fluorpyridin bzw. einem salz davon
CN100355732C (zh)	2003-11-03	2007-12-19	上海药明康德新药开发有限公司	2－氯－5－氟－烟酸酯及酸的制备方法
AU2006297443B2 (en)	2005-09-29	2010-08-12	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
DE102006043443A1 (de)	2006-09-15	2008-03-27	Bayer Healthcare Ag	Neue aza-bicyclische Verbindungen und ihre Verwendung
CA2694499A1 (en)	2007-07-31	2009-02-05	Vertex Pharmaceuticals Incorporated	Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2262498A2 (en)	2008-03-10	2010-12-22	Vertex Pharmceuticals Incorporated	Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5501369B2 (ja)	2008-11-25	2014-05-21	メルク・シャープ・アンド・ドーム・コーポレーション	可溶性グアニレートシクラーゼ活性化剤
US20130178475A1 (en)	2010-03-17	2013-07-11	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
EP2575473B1 (en) *	2010-05-27	2016-01-20	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
EP2590987B1 (de)	2010-07-09	2016-03-09	Bayer Intellectual Property GmbH	Annellierte 4-aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase
EP2708539A1 (de)	2010-07-09	2014-03-19	Bayer Intellectual Property GmbH	Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en) *	2011-01-11	2014-06-19	Bayer Pharma Aktiengessellschaft	Substituted imidazopyridines and imidazopyridazines and the use thereof
EP2699578B1 (de)	2011-04-21	2016-04-20	Bayer Intellectual Property GmbH	Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
JP6109161B2 (ja) *	2011-07-06	2017-04-05	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	ヘテロアリール置換ピラゾロピリジン類およびその使用

2012
- 2012-08-30 JP JP2014527659A patent/JP6054967B2/ja not_active Expired - Fee Related
- 2012-08-30 SG SG11201400083VA patent/SG11201400083VA/en unknown
- 2012-08-30 WO PCT/EP2012/066876 patent/WO2013030288A1/de not_active Ceased
- 2012-08-30 AP AP2014007541A patent/AP2014007541A0/xx unknown
- 2012-08-30 EA EA201490546A patent/EA026701B1/ru not_active IP Right Cessation
- 2012-08-30 PE PE2014000263A patent/PE20141582A1/es not_active Application Discontinuation
- 2012-08-30 KR KR1020147008313A patent/KR20140068112A/ko not_active Withdrawn
- 2012-08-30 CN CN201280053847.5A patent/CN104039784B/zh not_active Expired - Fee Related
- 2012-08-30 BR BR112014005110A patent/BR112014005110A2/pt active Search and Examination
- 2012-08-30 PH PH1/2014/500460A patent/PH12014500460A1/en unknown
- 2012-08-30 CA CA 2847075 patent/CA2847075A1/en not_active Abandoned
- 2012-08-30 MX MX2014002075A patent/MX348470B/es active IP Right Grant
- 2012-08-30 EP EP12766292.2A patent/EP2751106B1/de active Active
- 2012-08-30 AU AU2012300844A patent/AU2012300844B2/en not_active Ceased
- 2012-08-30 HK HK14112217.6A patent/HK1198698A1/xx unknown
- 2012-08-30 US US13/599,975 patent/US8859569B2/en not_active Expired - Fee Related
- 2012-08-31 UY UY0001034306A patent/UY34306A/es not_active Application Discontinuation
- 2012-08-31 TW TW101131665A patent/TWI565708B/zh not_active IP Right Cessation
- 2012-09-03 AR ARP120103249A patent/AR087769A1/es unknown
2014
- 2014-02-21 CO CO14037097A patent/CO6950471A2/es active IP Right Grant
- 2014-02-26 GT GT201400033A patent/GT201400033A/es unknown
- 2014-02-27 CR CR20140096A patent/CR20140096A/es unknown
- 2014-02-28 EC ECSP14013224 patent/ECSP14013224A/es unknown
- 2014-02-28 CL CL2014000504A patent/CL2014000504A1/es unknown
- 2014-02-28 MA MA36787A patent/MA35365B1/fr unknown
- 2014-02-28 DO DO2014000043A patent/DOP2014000043A/es unknown
- 2014-03-02 IL IL231244A patent/IL231244A/en not_active IP Right Cessation
- 2014-03-03 CU CUP2014000025A patent/CU20140025A7/es unknown
- 2014-09-19 US US14/491,558 patent/US20150105374A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150105374A1 (en)	2015-04-16
BR112014005110A2 (pt)	2017-04-18
NZ621396A (en)	2016-06-24
SG11201400083VA (en)	2014-06-27
IL231244A (en)	2017-09-28
CA2847075A1 (en)	2013-03-07
CN104039784A (zh)	2014-09-10
US8859569B2 (en)	2014-10-14
PH12014500460A1 (en)	2014-04-14
CR20140096A (es)	2014-03-25
EP2751106A1 (de)	2014-07-09
AP2014007541A0 (en)	2014-03-31
CU20140025A7 (es)	2014-05-27
MA35365B1 (fr)	2014-08-01
EA201490546A1 (ru)	2014-08-29
AU2012300844B2 (en)	2017-03-30
US20130338137A1 (en)	2013-12-19
JP2014527540A (ja)	2014-10-16
HK1198698A1 (en)	2015-05-29
MX348470B (es)	2017-06-13
MX2014002075A (es)	2015-01-12
EA026701B1 (ru)	2017-05-31
UY34306A (es)	2013-04-05
KR20140068112A (ko)	2014-06-05
GT201400033A (es)	2015-01-15
TWI565708B (zh)	2017-01-11
ECSP14013224A (es)	2014-03-31
JP6054967B2 (ja)	2016-12-27
DOP2014000043A (es)	2014-04-15
AR087769A1 (es)	2014-04-16
TW201326172A (zh)	2013-07-01
PE20141582A1 (es)	2014-11-06
WO2013030288A1 (de)	2013-03-07
EP2751106B1 (de)	2017-10-18
CN104039784B (zh)	2017-08-22
CO6950471A2 (es)	2014-05-20
IL231244A0 (en)	2014-04-30

Publication	Publication Date	Title
CL2014000504A1 (es)	2014-10-03	Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CL2014001779A1 (es)	2014-11-03	Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CL2015001163A1 (es)	2015-08-28	Compuestos derivados de imidazo[1,2-a]piridincarboxamidas aminosustituidas; procedimiento para prepararlos; medicamento; procedimiento para el tratamiento y/o la prevencion; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina de pecho, hipertension e hipertension pulmonar, entre otras enfermedades.
CL2015000120A1 (es)	2015-06-26	Compuestos derivados de acidos 5-aminotetrahidroquinolin-2-carboxilicos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de hipertension pulmonar, insuficiencia cardiaca, angina de pecho, hipertension, enfermedades tromboembolicas, enfermedades fibroticas, isquemias, entre otras.
CL2013000083A1 (es)	2013-04-12	Compuestos derivados de pirimidinas y triazinas condensadas; procedimiento para prepararlos; medicamento que los comprende; procedimiento de tratamiento y/o prevencion; y su uso para el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, hipertension pulmonar e isquemias, entre otras enfermedades.
CL2014003031A1 (es)	2015-03-06	Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
CL2013003598A1 (es)	2014-07-11	Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2012002356A1 (es)	2013-05-17	Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2014001389A1 (es)	2014-10-03	Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing.
CL2012003226A1 (es)	2013-07-26	Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2014000849A1 (es)	2014-08-29	Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2008001215A1 (es)	2008-09-22	Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer.
CL2013003262A1 (es)	2014-08-08	Compuestos derivados de 1,3-oxazinas, con actividad inhibidora de bace 1 y/o bace2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes, trombosis arterial, cáncer, infarto al miocardio, entre otras patologías.
CL2013000104A1 (es)	2013-05-17	Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
CL2013001715A1 (es)	2013-12-20	Compuestos derivados de indol, inhibidores de la replicacion del rsv; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la infeccion por el virus sincicial respiratorio.
CL2014000604A1 (es)	2014-10-17	Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing.
CL2013001654A1 (es)	2014-03-28	Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2012002716A1 (es)	2013-01-25	Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201390821A1 (ru)	2013-10-30	Антагонисты рецепторов лизофосфатидной кислоты и их применение